PPARγ accelerates OSCC progression via Th17 polarization and CEBPA/IL-17C signaling
This study identifies a novel PPARγ/CEBPA/IL-17C/IL-17A signaling axis that promotes Th17 differentiation and contributes to tumor-associated inflammation in OSCC. Targeting PPARγ represents a promising strategy to inhibit tumor progression and modulate the immune microenvironment, providing new insight into immunotherapeutic approaches for OSCC.
Authors
- Fanqian Cheng
- Jing Li (ORCID: https://orcid.org/0009-0009-9550-1468)
- Xin Zeng (ORCID: https://orcid.org/0009-0002-5881-8182)
- Ying Wang (ORCID: https://orcid.org/0000-0001-7808-6279)
- Shiyu Zhang (ORCID: https://orcid.org/0009-0008-5766-6061)
- Jing Liang (ORCID: https://orcid.org/0000-0002-0102-6523)
- Ning Ji (ORCID: https://orcid.org/0000-0002-2896-5205)
- Yingxin Zhang (ORCID: https://orcid.org/0000-0002-9424-7412)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan University (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1007/s00432-025-06296-6
- Citations
- 3
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- National Natural Science Foundation of China
- Sichuan University
- West China Hospital, Sichuan University